Organon updates outlook as FDA delays VTAMA label expansion
Organon (NYSE:OGN) projected a roughly 75 basis-point headwind to the company’s 2025 EBITDA margin on Tuesday after the FDA ...
Zacks.com on MSN5d
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
Organon (OGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...
Organon's (NYSE:OGN) Earnings Are Weaker Than They Seem
Despite announcing strong earnings, Organon & Co.'s ( NYSE:OGN ) stock was sluggish. We did some digging and found ...
bovnews3d
What’s Causing Organon & Co (OGN) Stock’s -19.31% Drop Over the Last Six Months?
On Tuesday, Organon & Co (OGN) stock saw a decline, ending the day at $16.46 which represents a decrease of $-0.46 or -2.72% from the prior close of $16.92. The stock opened at $16.74 and touched a ...
Philippine Daily Inquirer1d
Organon launches her health finder to improve access to women’s reproductive healthcare
Organon Philippines, a women’s health company, recently unveiled its Her Health Finder, an online tool that aims to empower ...
Organon reports FDA extension of target action date of review of Vtama sNDA
Organon (OGN) announced that the FDA extended by three months the target action date of its review of the supplemental New Drug Application, or ...
Organon: FDA Extends Vtama Atopic-Dermatitis Review to March
Organon, which is seeking approval of Vtama as a treatment for atopic dermatitis, said the FDA set a new target action date of March 12 for a decision after requesting the final datasets and ...
JD Supra2d
FDA Accepts BLA for Shanghai Henlius Biotech’s and Organon’s HLX14, a Denosumab Biosimilar
On October 30, 2024, Shanghai Henlius Biotech and Organon announced that the FDA has accepted the Biologic License Application (BLA) for HLX14, a proposed biosimilar to PROLIA/XGEVA (denosumab). In ...
Organon: Navigating Growth Opportunities and Financial Pressures with a Hold Rating
Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Organon (OGN – Research Report), reducing the price target to $17.00.
Earnings Update: Organon & Co. (NYSE:OGN) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Organon & Co. ( NYSE:OGN ) shareholders are probably feeling a little disappointed, since its shares fell 3.1% ...
Morningstar2d
Organon & Co Ordinary Shares
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Morningstar4d
Organon & Co Ordinary Shares
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...